Adherence to guidelines and registry data. - Wikidata - awgldk - TriplyDB

Adherence to guidelines and registry data.

Adherence to guidelines and registry data.

http://www.wikidata.org/entity/Q47966650

about

Adherence to guidelines and registry data.

http://www.wikidata.org/entity/Q47966650

description

2017 nî lūn-bûn

@nan

2017 թվականի հոկտեմբերին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

name

Adherence to guidelines and registry data.

@en

Adherence to guidelines and registry data.

@nl

type

label

Adherence to guidelines and registry data.

@en

Adherence to guidelines and registry data.

@nl

prefLabel

Adherence to guidelines and registry data.

@en

Adherence to guidelines and registry data.

@nl

P1433

Q47966650-9E6ACBDD-C697-4BAC-8202-47FF13EA9300

P1476

Q47966650-E129DF21-D8FC-473C-9B7A-6BFD875B468B

P2093

Q47966650-01023785-39C0-4A43-9AFD-423203035786

P2860

Q47966650-0E49FCF5-99C5-461D-AB0D-8E6306D20DF6

Q47966650-1D2CC935-E06A-4116-A639-43B7689F43B7

Q47966650-3943CE61-E183-44A3-A3F7-5E531E407DF3

Q47966650-522F3EE2-EAEA-4336-8518-5EA57CC91BA3

Q47966650-62194315-6243-4F14-A3BA-ACF61DC4A98A

Q47966650-658EBE94-25F2-4674-8E2D-000865B4D58F

Q47966650-7892A3FB-B37D-48F1-A086-B332A6823B48

Q47966650-FBDED200-68EF-4FD9-8233-1220578866B8

P304

Q47966650-E33A3691-24CA-48A6-BD4B-FBC59D48BD33

P31

Q47966650-1EAEA495-FC86-4789-9964-56EBC593BFF8

Q47966650-ee139c27-374d-4088-b4e3-dba58913c006

P356

Q47966650-F05A1204-9DDE-4EAF-BA60-9DAD8A81BF99

P433

Q47966650-B2015066-81AA-4093-A141-1560190B89D5

P478

Q47966650-6072FE91-DE01-4345-A950-B654169C5160

P577

Q47966650-F6DADC41-F683-4CD6-A64F-E116AEEF41D0

P698

Q47966650-6A820055-158F-4593-A455-356C90A512E4

P356

P1433

European heart journal. Cardiovascular pharmacotherapy

P1476

Adherence to guidelines and registry data.

@en

P2093

Stefan Agewall

http://www.w3.org/2001/XMLSchema#string

P2860

Dual antiplatelet therapy: optimal timing, management, and duration

P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries.

Optimization of heart failure medication after cardiac resynchronization therapy and the impact on long-term survival.

Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary European registries.

Contemporary registries on P2Y12 inhibitors in patients with acute coronary syndromes in Europe: overview and methodological considerations.

Determinants of agreement between proposed therapeutic windows of platelet function tests in vulnerable patients.

Risk factor changes and incident atrial fibrillation among middle-aged men in the Malmö Preventive Project cohort.

Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study.

P304

183-184

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EHJCVP/PVX027

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28922837

http://www.w3.org/2001/XMLSchema#string